Back to Resource Center

HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial

A potential concern with the use of dapivirine (DPV) for HIV prevention is the selection of a drug-resistant virus that could spread and reduce the effectiveness of non-nucleoside reverse transcriptase (NNRTI)-based first-line antiretroviral therapy. We evaluated HIV-1 seroconversions in MTN-020/ASPIRE for selection of drug resistance and evaluated the genetic basis for observed reductions in susceptibility to DPV.

November 2021

Click for full info +

Full Info:


Resource Type:

Database
Journal Article
Journal Article
Resource

Citation:

A potential concern with the use of dapivirine (DPV) for HIV prevention is the selection of a drug-resistant virus that could spread and reduce the effectiveness of non-nucleoside reverse transcriptase (NNRTI)-based first-line antiretroviral therapy. We evaluated HIV-1 seroconversions in MTN-020/ASPIRE for selection of drug resistance and evaluated the genetic basis for observed reductions in susceptibility to DPV.

View Journal Article

Authors: Parikh, UM; Penrose, KJ ; Heaps, AL ; Halvas, EK ; Goetz, BJ; Gordon, KC ; Hardesty, R ; Sethi, R ; Schwarzmann, W ; Szydlo, DW ; Husnik, MJ ; Chandran, U ; Palanee-Phillips, T ; Baeten, JM ; Mellors, JW ; the MTN-020 Study Team

Health Risks(s):

  • HIV

Product type(s):

  • IVR

Topic(s):

  • DrugInteractions
  • Development

Region(s)

  • Africa

Back to Resource Center